Abstract library

132 results for "Valle".
#264 Alterations of TIMP-3 Gene in Insulinomas and Its Significance
Introduction: Our previous study on insulinoma found allelic loss of 22q12 where suppressor gene TIMP3 located. TIMP3 can inhibit tumor invasion or metastasis, but its clinical implications in insulinoma are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Zhou C Y, Wu H Y, Liu T H, ...
#527 Pheochromocytoma Molecular Analysis After Maternal Transmission of SDHD Mutation Elucidates Mechanism of Parent-of-Origin Effect
Introduction: In SDHD mutation families, paragangliomas and pheochromocytomas usually occur only after paternal transmission of the mutation. This important but unexplained parent-of-origin effect is not due to imprinting of the SDHD gene itself (as was initially suspected) since SDHD is biallelically expressed.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Edward Tobias
Authors: Tobias E, Yeap P, Mavraki E, Fletcher A, ...
#2034 International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)
Introduction: Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for EP-G3-NEC; the optimal schedule has not been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Angela Lamarca
#31 Patterns and predictors of failure after curative resections of pancreatic endocrine carcinoma
Introduction: Pancreatic endocrine carcinomas (PECs) are generally associated with a good prognosis, above all after radical resection. In other pancreatic malignancies, predictors of failure and the role of lymph node ratio (LNR) are well-known, but prognostic factors and the value of LNR, as well as patterns of recurrence after surgery for PEC has never been investigated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Massimo Falconi
#89 Hyperplasia-adenoma sequence in pituitary carcinogenesis: new insight into the role of AIP gene
Introduction: Pituitary adenoma predisposition has been recently associated with germline mutations in the Aryl-Hydrocarbon Receptor Interacting Protein (AIP) gene. This association has been detected in familial and, more rarely, in sporadic cases. The mechanisms by which the AIP mutations promote pituitary adenoma development remain unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Chiara Villa
#122 Molecular genetic findings in gastric carcinoid suggest possible neurofibromin/Ras pathway involvement in carcinoid pathogenesis
Introduction: The molecular pathogenesis of gastrointestinal carcinoid tumours is poorly understood. We have been undertaking molecular genetic investigations of a young woman with neurofibromatosis type 1 (NF1) in whom a gastric carcinoid tumor was detected following an episode of gastrointestinal bleeding. She was otherwise relatively mildly affected by NF1. In NF1, gastric carcinoids have been found previously only in patients with other predisposing factors, which were absent in this patient.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Edward S Tobias
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#170 Swiss Neuroendocrine Tumor (SwissNET) registry: Results after 30 Months
Introduction: The Swiss registry for NETs (SwissNET) was established in 2008 to improve epidemiological data on NET patients in Switzerland. Here the results after 30 months of follow-up are presented.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christoph Stettler
#336 Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jack Ishak
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson